Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-26
2000-02-15
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514336, A01N 4316, A01N 4340
Patent
active
060253886
ABSTRACT:
Retinoid compounds which repress expression of the gene promoted by AP1 protein but which do not significantly activate expression of the genes having RA-responsive elements in their promoter region through RAR.alpha. and RAR.GAMMA. receptor subtypes, are used, with reduced side effects, for treating diseases and conditions which are responsive to therapy with retinoids.
REFERENCES:
patent: 4096341 (1978-06-01), Frazer
patent: 4326055 (1982-04-01), Loeliger
patent: 4391731 (1983-07-01), Boller et al.
patent: 4695649 (1987-09-01), Magami et al.
patent: 4723028 (1988-02-01), Shudo
patent: 4739098 (1988-04-01), Chandraratna
patent: 4740519 (1988-04-01), Schroot et al.
patent: 4810804 (1989-03-01), Chandraratna
patent: 4826969 (1989-05-01), Maignan et al.
patent: 4826984 (1989-05-01), Berlin et al.
patent: 4855320 (1989-08-01), Chatterjee et al.
patent: 4895868 (1990-01-01), Chandraratna
patent: 4927947 (1990-05-01), Chandraratna
patent: 4980369 (1990-12-01), Chandraratna
patent: 4992468 (1991-02-01), Chandraratna
patent: 5006550 (1991-04-01), Chandraratna
patent: 5013744 (1991-05-01), Chandraratna
patent: 5015658 (1991-05-01), Chandraratna
patent: 5023341 (1991-06-01), Chandraratna
patent: 5037825 (1991-08-01), Klaus et al.
patent: 5045551 (1991-09-01), Chandraratna
patent: 5053523 (1991-10-01), Chandraratna
patent: 5068252 (1991-11-01), Chandraratna
patent: 5089509 (1992-02-01), Chandraratna
patent: 5130335 (1992-07-01), Chandraratna
patent: 5134159 (1992-07-01), Chandraratna
patent: 5162546 (1992-11-01), Chandraratna
patent: 5175185 (1992-12-01), Chandraratna
patent: 5183827 (1993-02-01), Chandraratna
patent: 5202471 (1993-04-01), Chandraratna
patent: 5231113 (1993-07-01), Chandraratna
patent: 5234926 (1993-08-01), Chandraratna
patent: 5248777 (1993-09-01), Chandraratna
patent: 5264456 (1993-11-01), Chandraratna
patent: 5264578 (1993-11-01), Chandraratna
patent: 5272156 (1993-12-01), Chandraratna
patent: 5278318 (1994-01-01), Chandraratna
patent: 5324744 (1994-06-01), Chandraratna
patent: 5324840 (1994-06-01), Chandraratna
patent: 5326898 (1994-07-01), Chandraratna
patent: 5344959 (1994-09-01), Chandraratna
patent: 5346895 (1994-09-01), Chandraratna
patent: 5346915 (1994-09-01), Chandraratna
patent: 5348972 (1994-09-01), Chandraratna
patent: 5348975 (1994-09-01), Chandraratna
patent: 5349105 (1994-09-01), Chandraratna
patent: 5354752 (1994-10-01), Chandraratna
patent: 5380877 (1995-01-01), Chandraratna
patent: 5391753 (1995-02-01), Chandraratna
patent: 5399561 (1995-03-01), Chandraratna
patent: 5399586 (1995-03-01), Davies et al.
patent: 5407937 (1995-04-01), Chandraratna
patent: 5414007 (1995-05-01), Chandraratna
patent: 5426111 (1995-06-01), Dellaria et al.
patent: 5426118 (1995-06-01), Chandraratna
patent: 5434173 (1995-07-01), Chandraratna
patent: 5534641 (1996-07-01), Song et al.
Yang-Yen et al. (1991) The New Biologist, 3/12: 1206-1219.
Karin et al. (1993) Eur. J. Clin. Pharmacol., 45[Supp]: S9-S15.
Herrlich et al. (1994) TEM, 5/8: 341-346.
Nicholson et al. (1990) The EMBO Journal, 9/13: 4443-4454.
A General Synthesis of Terminal and Internal Arylalkynes by the Palladium-Catalyzed Reation of Alkynylzinc Reagents with Aryl Halides by Anthony O. King and Ei-ichi Negishi, J. Org. Chem. 43 No. 2, 1978 p. 358.
Conversion of Methyl Ketones into Terminal Acetylenes and (E)-Tri-substituted Olefins of Terpenoid Origin by Ei-ichi, Anthony O. King, and William L. Klima, J. Org. Chem. 45 No. 12, 1980 p. 2526.
Sporn et. al. in J. Amer. Acad. Derm. 15:756-764 (1986).
A Convenient Synthesis of Ethynylarenes and Diethynylarenes by S. Takahashi, Y. Kuroyama, K. Sonogashira, N. Hagihara, Synthesis 1980 pp. 627-630.
Shudo et al. in Chem. Phar. Bull. 33:404-407 (1985).
Kagechika et. al. in J. Med. Chem. 31:2182-2192 (1988).
Chemistry and Biology of Synthetic Retinoids by Marcia I. Dawson and William H. Okamura, published by CRC Press Inc., 1990, pp. 334-335, 354.
Synthesis of 2,2'-Diacyl-1,1'-biaryls. Regiocontrolled Protection of . . . by Mervic, et al, J. Org. Chem., No. 45, pp. 4720-4725, 1980.
A Dopamine Receptor Model and Its Application in the Design of a New Class of Rigid Pyrrolo[2,3-g]isoquinoline Antipsychotics, Gary L. Olson, et al. American Chemical Society, 1981, Vo. 24, No. 9, pp. 1026-1031.
6.2.3 Conformational Restriction, Williams, et al., Drug Discovery and Development, 1987 The Humana Press, pp. 54-55.
V. Retinoid Structure-Biological Activity Relationships, Chemistry and Biology of Synthetic Retinoids, pp. 324-356, 1990.
Davis et al. J. Organomettalic Chem 387 (1990) 381-390.
Effects of 13-Cis-Retinoic Acid, All-Trans-Retinoic Acid, and Acitretin on the Proliferation, Lipid Synthesis and Keratin Expression of Cultured Human Sebocytes In Vitro, C. C. Zouboulis, The Journal of Investigative Dermatology, vol. 96, No. 5, May 1991, pp. 792-797.
Organ maintenance of human sebaceous glands: in vitro effects of 13-cis retinoic acid and testosterone, John Ridden, et al., Journal of Cell Science, Vo. 95, 1990, pp. 125-136.
Characterization of Human Sebaceous Cells In Vitro, Thomas I. Doran, et al., The Journal of Investigative Dermatology, vol. 96, No. 3, Mar., 1991.
Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents That Inhibit Tubulin Polymerization by Cushman, Mark et.al. J.Med. Chem 1991, 34, 2579-2588.
Synthesis and Evaluation of New Protein-Tyrosine Kinase Inhibitors. Part 1. Pyridine-Containing Stilbenes and Amides by Cushman, Mark et al. Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 4, pp. 211-214, 1991.
Di-and Tri-methoxystyryl Derivatives of Heterocyclic Nitrogen Compounds by Bahner, C.T. et al. Arzneim-Forsch./Drug Res, 31 (I), Nr. 3 (1981).
Retinobenzoic acids. 3. Structure-Activity Relationships of retinoidal Azobenzene-4-carboxylic acids and Stilbene-4-carboxylic acids by H. Kagechika et al., Journal of Medicinal Chemistry, 1989, 32, pp. 1098-1108.
Roshantha A.S. Chandraratna, et al., "Development of RAR Subtype Selective Retinoids for Dermatological Diseases", Eur. J. Med. Chem., (1995) vol. 30.
Proceedings of the 13th International Symposium on Medical Chemistry, 1994):505S-17S.
Jia-Yang Chen, et al., "RAR-specific agonist/antagonists which dissociate transactivation and API transrepression inhibit anchorage-independent cell proliferation", The EMBO Journal, (1995) 14/6:1187-1197.
Reuben Lotan, et al., "Retinoic Acids Receptors and Retinoid-Regulated Differentiation Markers as Intermediate Endpoints in Chemoprevention", Proceedings of the American Association for Cancer Research, (1994) vol. 35:684-685.
Andrea Fanjul, et al., "A New Class of Retinoids with Selective Inhibition of AP-1 Inhibits Proliferation", Nature, (1994) 372/3:107-111.
Sunil Nagpal, et al. "Spearation of Transactivation and AP1 Antagonism Functions of Retinoic Acid Receptor .alpha.*", The Journal of Biological Chemistry, (1995) 270/2:923-927.
Fanjul A. et al. "The Ying-yan of RAR and AP-1: cancer treatment without overt toxicity", Human & Experimental Toxicology, (1995) 14/2:226-230.
Athanikar Jyoti
Chandraratna Roshantha A.
Nagpal Sunil
Song Tae K.
Vuligonda Vidyasagar
Allergan Sales Inc.
Baran Robert J.
Szekeres Gabor L.
Travers Russell
Voet Martin A.
LandOfFree
Method for inhibiting gene expression promoted by AP1 protein wi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting gene expression promoted by AP1 protein wi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting gene expression promoted by AP1 protein wi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1906413